<code id='C8D5449DEB'></code><style id='C8D5449DEB'></style>
    • <acronym id='C8D5449DEB'></acronym>
      <center id='C8D5449DEB'><center id='C8D5449DEB'><tfoot id='C8D5449DEB'></tfoot></center><abbr id='C8D5449DEB'><dir id='C8D5449DEB'><tfoot id='C8D5449DEB'></tfoot><noframes id='C8D5449DEB'>

    • <optgroup id='C8D5449DEB'><strike id='C8D5449DEB'><sup id='C8D5449DEB'></sup></strike><code id='C8D5449DEB'></code></optgroup>
        1. <b id='C8D5449DEB'><label id='C8D5449DEB'><select id='C8D5449DEB'><dt id='C8D5449DEB'><span id='C8D5449DEB'></span></dt></select></label></b><u id='C8D5449DEB'></u>
          <i id='C8D5449DEB'><strike id='C8D5449DEB'><tt id='C8D5449DEB'><pre id='C8D5449DEB'></pre></tt></strike></i>

          entertainment

          entertainment

          author:Wikipedia    Page View:85878
          Exterior photo of UnitedHealth Group building
          UnitedHealth Group is attempting to buy Amedisys for $3.3 billion. Courtesy UnitedHealth Group

          There’s now a two-party showdown for one of the largest home health companies in the country.

          UnitedHealth Group and its Optum division on Monday formally proposed to buy Amedisys for $100 per share, or about $3.3 billion.

          advertisement

          The offer comes a few weeks after Option Care Health proposed a $3.6 billion takeover. However, Option Care’s deal is an all-stock transaction, whereas UnitedHealth would pay all cash — a potentially more attractive offer for Amedisys shareholders who want a more immediate payout that isn’t tied to the unpredictability of another company’s stock price. Option Care’s offer is technically worth closer to $2.8 billion now, due to the drop in Option Care’s stock price since the merger was announced. Amedisys is recommending shareholders vote in favor of the deal with Option Care.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          comprehensive

          Cancer drug shortages should be causing more outrage
          Cancer drug shortages should be causing more outrage

          DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

          read more
          The history of OxyContin, told through Purdue Pharma documents
          The history of OxyContin, told through Purdue Pharma documents

          AlexHogan/STATPIKEVILLE,Ky.—STAT’smultiyearlegalbattletounsealsecretPurduePharmafilesinaKentuckycour

          read more
          Supreme Court strikes down use of affirmative action
          Supreme Court strikes down use of affirmative action

          ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

          read more

          Where are patients getting their prescriptions for GLP

          AdobeAsanewclassofdiabetesandobesitymedicationshassoaredinpopularity,sohavetheonlineoutletsbuilttoge